Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2019-11-19 Report Publication Anno…
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Invitation to third quarter 2019 results presentation
Report Publication Announcement Classification · 98% confidence The document is titled "PCI Biotech: Invitation to third quarter 2019 results presentation". It explicitly invites stakeholders to a presentation regarding the company's third quarter 2019 results and provides details on the time, venue, and webcast. Crucially, it states: "The interim report and the presentation will be available on www.newsweb.no and on the company's webpage... on 27 November 2019." This structure—announcing an upcoming event where a report (the interim report) will be discussed/released—fits the definition of a Report Publication Announcement (RPA) better than the Interim Report (IR) itself, especially given the short document length (3534 chars) and the focus on the invitation/announcement logistics. It is announcing the publication/presentation of the Q3 results report.
2019-11-19 English
PCI Biotech to present at BIO-Europe 2019
Regulatory Filings Classification · 100% confidence The document is a short announcement from PCI Biotech stating that the company will present at the BIO-Europe 2019 conference on a specific date and time. It details the presenter (CEO) and the topic (technology overview and business opportunities). It also mentions that the presentation will be made available on the company's website under 'Other presentations'. Since this is a brief announcement about an upcoming presentation/event, and not the presentation itself, nor a formal financial report (like 10-K, ER, IR), it best fits the category for general corporate updates or investor-related news that isn't a formal filing. Given the options, this type of announcement about participation in an industry event is most closely aligned with general investor communication, which often falls under Regulatory Filings (RNS) if no other specific category fits, or potentially Investor Presentation (IP) if it were the presentation material itself. However, since it is an announcement *about* presenting, and it is short, it functions as a general regulatory/corporate update. RNS is the best fallback for non-standard, non-financial-report announcements.
2019-11-12 English
PCI Biotech to present at World Vaccine Congress Europe
Regulatory Filings Classification · 95% confidence The document is a short press release dated October 28, 2019, announcing that PCI Biotech will present its vaccine technology at the World Vaccine Congress Europe. It details the presentation topic, presenter, date, and location. It also provides background information on the company and its technology platforms. Since this is an announcement about participation in an external industry event (a presentation), and not a formal regulatory filing like a 10-K, ER, or IR, it best fits the category for general corporate news or announcements that don't fit elsewhere. Given the options, it is a general corporate announcement. While it is not explicitly an 'Earnings Release' (ER) or 'Interim Report' (IR), it is a specific corporate update. Since it is an announcement about an upcoming presentation at a conference, it is most closely related to investor relations communication. However, none of the categories perfectly match 'Conference Presentation Announcement'. Given the available codes, 'RNS' (Regulatory Filings / General regulatory announcements and fallback category) is the most appropriate fallback for specific, non-standard corporate news that isn't a financial report, management change, or dividend notice. It is not a proxy statement (PSI), director dealing (DIRS), or capital change (CAP). It is a specific corporate event announcement.
2019-10-28 English
PCI Biotech to present at World Vaccine Congress Europe
Regulatory Filings Classification · 100% confidence The document announces that PCI Biotech will present its vaccine technology at the World Vaccine Congress Europe. It details the presentation topic, time, location, and who will be presenting. This is a communication to investors and the public about participation in an industry event, which is not explicitly covered by the core financial filing types (10-K, ER, IR, etc.). Since it is an announcement about an upcoming event/presentation, and it doesn't fit into specific categories like Director's Dealing, Dividend Notice, or Capital Change, it falls best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially 'Investor Presentation' (IP) if the content was the presentation itself, but here it is an announcement *about* the presentation. Given the nature of the announcement (event participation), RNS is the most appropriate general regulatory filing fallback.
2019-10-28 English
PCI Biotech: Mandatory notification regarding trade of shares
Director's Dealing Classification · 98% confidence The document text describes a transaction involving shares in PCI Biotech Holding ASA by a board member (Lars Viksmoen) and a related entity (Stocken Invest AS). It explicitly states the number of shares transferred and the price, and mentions disclosure requirements under the Norwegian Securities Trading Act. This content directly relates to reporting personal share transactions by company directors and executives (insider trades). This matches the definition for Director's Dealing (DIRS). The document length is very short (764 chars), but the content is specific enough to classify it directly rather than defaulting to a general announcement code.
2019-10-18 English
PCI Biotech: Mandatory notification regarding trade of shares
Director's Dealing Classification · 100% confidence The document explicitly states it is a 'Mandatory notification regarding trade of shares' involving a board member (Lars Viksmoen) and an affiliated entity (Stocken Invest AS). It details the transfer of shares and the resulting holdings, referencing disclosure requirements under securities trading law. This directly matches the definition of Director's Dealing (insider trades by executives/directors).
2019-10-18 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.